Step therapy forces migraine patients to fail cheap drugs before the right one.

The pharmacy counter where it starts

You hand over the prescription your neurologist spent a whole appointment deciding on. The pharmacist scans it, pauses, and says the words you'll come to hate: "Your insurance needs you to try something else first."

Not because the drug is unsafe. Not because your specialist got it wrong. Because a formulary somewhere ranks the cheaper option above the one written for you, and the plan wants proof that the cheap one failed before it'll pay for the right one. So you go home with nothing, or with a drug your doctor already knows won't hold. And the attacks keep coming while you wait.

Call it what it is: fail-first

The insurance industry calls this "step therapy." The clinical shorthand, the one that's more honest, is fail-first. You don't step up to better care. You're required to fail on inferior care before the plan will unlock what your clinician actually chose.

Gaslighting is the right word for how it feels, because the process quietly reframes a coverage decision as a medical one. The denial letter talks about "clinical appropriateness" and "preferred alternatives," language that makes it sound like your doctor overreached. They didn't. A budget did.

Fail-first isn't a safety protocol. It's a budget line dressed as one.

Why "it's just cost management" doesn't hold

Plans defend step therapy as evidence-based cost control: start with what's cheap and proven, escalate only if needed. That logic collapses on the CGRP class specifically.

The drugs at the bottom of the fail-first ladder, the old oral preventives like tricyclics, beta-blockers, and topiramate, were never designed for migraine. They're borrowed from other conditions, and their side-effect load is why so many people abandon them. CGRP-targeting therapies, the monoclonal antibodies (erenumab, galcanezumab, fremanezumab, eptinezumab) and the gepants (rimegepant, atogepant), were built for this. Making someone grind through months of a drug that fogs their cognition, when their prescriber already ruled it out, isn't caution. It's delay with a clinical costume on.

What the specialty societies actually say

Here's the part that turns the argument in your favor. The American Headache Society has moved away from requiring patients to fail older oral preventives before accessing CGRP-targeted treatment. The AHS 2024 position statement, 'Calcitonin gene-related peptide-targeting therapies are a first-line option for migraine prevention,' states initiation should not require trial of older treatments. ([source](https://www.migrainedisorders.org/ahs-statement-cgrp/))

That matters because insurer step-therapy protocols on this class often lag the specialty consensus by years. When your plan requires you to fail Most insurance plans require documented failure or intolerance of at least two preventive medication trials before approving coverage for CGRP treatments. older preventives first, it's enforcing a rule that the field's own governing body has stepped past. You're not asking for an exception to good medicine. You're asking the plan to catch up to it.

How to argue around it, step by step

You don't beat fail-first by calling and pleading. You beat it with a paper trail the plan can't wave away. The mechanism is a step-therapy override, usually requested through a letter of medical necessity your prescriber signs. Here's what goes in it, and why each piece does work.

Get your neurologist's office to write it, but bring them the raw material. They see dozens of patients; you remember exactly which drug gave you the tremor and which one you quit after three weeks. Your record of what you tried and what it did to you is the spine of the whole appeal.

What changes when the letter lands

When a well-built medical-necessity letter goes in, one of two things happens. The plan approves the override, and you get the drug your specialist chose without the months of manufactured failure. Or it denies, and you escalate to external review, where an independent physician who doesn't work for the insurer looks at the same file. That's where documented denials start to reverse.

Either path runs on the same fuel: a specific, dated, symptom-level record. Vague memory loses appeals. "I think that one made me tired" is not evidence. "Topiramate, 100mg, eight weeks, cognitive slowing that made work impossible, discontinued in March" is.

Where the record comes from

The reason most patients walk into this fight unarmed is that the record doesn't exist yet. Migraine tracking that stops when the headache stops misses the exact material an appeal needs: how long the after-effects dragged on, the residual photophobia, the brain fog that kept you from working the next day, the days you lost after the pain was technically "gone."

We built Postdrome to keep the timeline running through the whole arc, not just the attack peak, because that continuous record is what turns "I was in bad shape" into a defensible frequency-and-disability picture. It stays on your device, and it exports, so when your neurologist's office builds the letter, you're handing them dates and durations instead of asking them to reconstruct a year from memory.